FDA Inspection
Primus Pharmaceuticals, Inc.Primus Pharmaceuticals, Inc. – FDA Inspection, Jul 23, 2026
Record Details
This FDA Inspection record concerns Primus Pharmaceuticals, Inc., with an inspection on July 23, 2026, issued by the Denver District Office, covering human drugs.
- Office
- Denver District Office
View Company Profile
ID · 39dbcc97-e845-44b0-af6c-26a126e3a1e6
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1289866
- FDA center
- Human Drugs
- Project area
- Postmarket Surv. and Epidemiology
- Outcome
- Form 483 issued
FDA Citations
1- 21 CFR 314.80(b)Failure to develop written procedures
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Primus Pharmaceuticals, Inc.
1| Date | Classification | Office | Project area |
|---|---|---|---|
| March 23, 2018 | Not classified | Denver District Office |
Other documents for Primus Pharmaceuticals, Inc.
- FDA Inspection 1048884 - 2018-03-23
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.